745 related articles for article (PubMed ID: 27083005)
21. Protein Footprinting and X-ray Crystallography Reveal the Interaction of PD-L1 and a Macrocyclic Peptide.
Niu B; Appleby TC; Wang R; Morar M; Voight J; Villaseñor AG; Clancy S; Wise S; Belzile JP; Papalia G; Wong M; Brendza KM; Lad L; Gross ML
Biochemistry; 2020 Feb; 59(4):541-551. PubMed ID: 31841311
[TBL] [Abstract][Full Text] [Related]
22. Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?
Chen T; Li Q; Liu Z; Chen Y; Feng F; Sun H
Eur J Med Chem; 2019 Jan; 161():378-398. PubMed ID: 30384043
[TBL] [Abstract][Full Text] [Related]
23. Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
Wang T; Cai S; Wang M; Zhang W; Zhang K; Chen D; Li Z; Jiang S
J Med Chem; 2021 Jun; 64(11):7390-7403. PubMed ID: 34056906
[TBL] [Abstract][Full Text] [Related]
24. Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.
Shi D; Zhou S; Liu X; Zhao C; Liu H; Yao X
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):576-588. PubMed ID: 29203283
[TBL] [Abstract][Full Text] [Related]
25. Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy.
Chen R; Yuan D; Ma J
Future Med Chem; 2022 Jan; 14(2):97-113. PubMed ID: 34870447
[TBL] [Abstract][Full Text] [Related]
26. Molecular dynamics simulations elucidate conformational selection and induced fit mechanisms in the binding of PD-1 and PD-L1.
Liu W; Huang B; Kuang Y; Liu G
Mol Biosyst; 2017 May; 13(5):892-900. PubMed ID: 28327740
[TBL] [Abstract][Full Text] [Related]
27. Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization.
Guo Y; Jin Y; Wang B; Liu B
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946261
[TBL] [Abstract][Full Text] [Related]
28. Discovery of [1,2,4]Triazolo[4,3- a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
Qin M; Cao Q; Zheng S; Tian Y; Zhang H; Xie J; Xie H; Liu Y; Zhao Y; Gong P
J Med Chem; 2019 May; 62(9):4703-4715. PubMed ID: 30964291
[TBL] [Abstract][Full Text] [Related]
29. A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery.
Tang S; Kim PS
Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24500-24506. PubMed ID: 31727844
[TBL] [Abstract][Full Text] [Related]
30. SAR study of small molecule inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction.
Kawashita S; Aoyagi K; Fukushima K; Hantani R; Naruoka S; Tanimoto A; Hori Y; Toyonaga Y; Yamanaka H; Miyazaki S; Hantani Y
Chem Biol Drug Des; 2021 Nov; 98(5):914-929. PubMed ID: 34495575
[TBL] [Abstract][Full Text] [Related]
31. Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.
Wang T; Wu X; Guo C; Zhang K; Xu J; Li Z; Jiang S
J Med Chem; 2019 Feb; 62(4):1715-1730. PubMed ID: 30247903
[TBL] [Abstract][Full Text] [Related]
32. Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.
Guzik K; Tomala M; Muszak D; Konieczny M; Hec A; Błaszkiewicz U; Pustuła M; Butera R; Dömling A; Holak TA
Molecules; 2019 May; 24(11):. PubMed ID: 31151293
[TBL] [Abstract][Full Text] [Related]
33. Identification of the FDA-Approved Drug Pyrvinium as a Small-Molecule Inhibitor of the PD-1/PD-L1 Interaction.
Fattakhova E; Hofer J; DiFlumeri J; Cobb M; Dando T; Romisher Z; Wellington J; Oravic M; Radnoff M; Patil SP
ChemMedChem; 2021 Sep; 16(18):2769-2774. PubMed ID: 34117723
[TBL] [Abstract][Full Text] [Related]
34. Recent Advances in the Development of PD-L1 Modulators: Degraders, Downregulators, and Covalent Inhibitors.
Cheng B; Xiao Y; Xue M; Cao H; Chen J
J Med Chem; 2020 Dec; 63(24):15389-15398. PubMed ID: 33272018
[TBL] [Abstract][Full Text] [Related]
35. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
Tan S; Zhang H; Chai Y; Song H; Tong Z; Wang Q; Qi J; Wong G; Zhu X; Liu WJ; Gao S; Wang Z; Shi Y; Yang F; Gao GF; Yan J
Nat Commun; 2017 Feb; 8():14369. PubMed ID: 28165004
[TBL] [Abstract][Full Text] [Related]
36. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
Kopalli SR; Kang TB; Lee KH; Koppula S
Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
[TBL] [Abstract][Full Text] [Related]
37. Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction.
Muszak D; Surmiak E; Plewka J; Magiera-Mularz K; Kocik-Krol J; Musielak B; Sala D; Kitel R; Stec M; Weglarczyk K; Siedlar M; Dömling A; Skalniak L; Holak TA
J Med Chem; 2021 Aug; 64(15):11614-11636. PubMed ID: 34313116
[TBL] [Abstract][Full Text] [Related]
38. PD-1/PD-L1 inhibitor screening of caffeoylquinic acid compounds using surface plasmon resonance spectroscopy.
Han Y; Gao Y; He T; Wang D; Guo N; Zhang X; Chen S; Wang H
Anal Biochem; 2018 Apr; 547():52-56. PubMed ID: 29428377
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of isoxazole-containing biphenyl derivatives as small-molecule inhibitors targeting the programmed cell death-1/ programmed cell death-ligand 1 immune checkpoint.
Zhu P; Zhang J; Yang Y; Wang L; Zhou J; Zhang H
Mol Divers; 2022 Feb; 26(1):245-264. PubMed ID: 33786726
[TBL] [Abstract][Full Text] [Related]
40. Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors.
Almahmoud S; Zhong HA
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31546905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]